Regeneron recommends longer Libtayo dosing. Regeneron stock is valued at USD 83.1 billion
Published on 10/21/2026 at 11:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSDosing changes and dates
- Regeneron said on October 16, 2026, that Libtayo could use a 700 mg dose every six weeks after 12 weeks.
- Pasatru produced zero new lesions versus 9 for placebo at week 84 in the October 12, 2026 trial update.
- Regeneron stock traded at EUR 719.15 at 11:53 a.m. CEST at Lang & Schwarz on October 21, 2026.
- Piper Sandler lifted its target from USD 854.00 to USD 865.00 on October 19, 2026.
- Regeneron will report third-quarter 2026 results on October 30, 2026.
Regeneron (US75886F1075) is preparing a broader Libtayo dosing option in Europe, while its stock was trading at EUR 719.15 at Lang & Schwarz on October 21, 2026 at 11:53 a.m. CEST. The company said on October 16, 2026, that the European medicines committee recommended a 700 mg Libtayo dose every six weeks after an initial 12-week regimen.
Libtayo plan adds a dosing figure
According to Regeneron, the October 16, 2026 recommendation covers all approved cancer types. It also supports an infusion option of 15 to 30 minutes for patients receiving the 350 mg dose when the first infusion is well tolerated. A final European Commission decision is expected in the coming months.
Three October events changed the picture
On October 12, 2026, Regeneron reported zero new heterotopic ossification lesions for Pasatru versus 9 for placebo at week 84.
On October 16, 2026, the Libtayo recommendation proposed 700 mg every six weeks after 12 weeks. On October 19, 2026, Markets Insider reported that Piper Sandler raised its Regeneron target from USD 854.00 to USD 865.00 while maintaining an Overweight rating.
What comes next for Regeneron?
The next scheduled company date is October 30, 2026, when Regeneron will report third-quarter financial and operating results before U.S. markets open and host a call at 8:30 a.m. Eastern Time, according to Regeneron. The last reported quarter showed revenue of USD 4.29 billion in the second quarter of 2026, compared with USD 3.61 billion in the first quarter, while net income reached USD 1.30 billion.
Revenue gives the pipeline context
The second-quarter revenue figure matters because the October drug updates arrive before the next earnings release. The Economic Times lists Regeneron's second-quarter 2026 revenue at USD 4.29 billion and net income at USD 1.30 billion, giving investors a concrete operating base for judging the pipeline and commercial portfolio.
Stock value and next date
Regeneron had a market capitalization of USD 83.1 billion as of October 20, 2026, with a Nasdaq listing under ticker REGN. The stock was trading at EUR 719.15 at Lang & Schwarz on October 21, 2026 at 11:53 a.m. CEST.
The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.
Regeneron stock facts
- Company: Regeneron Pharmaceuticals, Inc.
- ISIN: US75886F1075
- Ticker: REGN
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 21, 2026, 11:53 a.m. CEST): EUR 719.15
- Market capitalization: USD 83.1 billion (as of October 20, 2026)
- Sector / Industry: Healthcare / Biotechnology
Market context: Market report S&P 500.
